NVCR News and Press, NovoCure Limited From 06/12/21

As it harnesses the power of an electromagnetic field, NovoCure offers hope to countless patients suffering from aggressive cancers. Tumor Treating Fields are now approved for deadly cancers, including glioblastoma multiforme and mesothelioma. The sales also are heading toward the blo...

Dogecoin (CRYPTO: DOGE) has been all over the news in 2021, and for good reason. By early May 2021, this meme-inspired cryptocurrency had gained over 12,000% since the start of 2021. And even now, when Dogecoin is more than 40% below its all-time high of $0.74, it is still 6,880% up...

Growth stocks are usually known to capitalize off short-term consumer trends. However, the best growth companies are the ones that set aside a portion of their revenues each quarter and reinvest back into innovation. That kind of discipline is extremely hard to come by. Luckily, ...

Novocure (NVCR) has entered into a clinical trial collaboration agreement with GT Medical Technologies to develop Tumor Treating Fields ((TTFields)) together with GT Medical's GammaTile Surgically Targeted Radiation Therapy ((STaRT)) for treatment of recurrent glioblastoma ((GBM)), an aggress...

SHANGHAI and SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today announced treatment of the first patient in Greater China in the METIS trial, a Phase 3 pivotal trial being conducted by Z...

Novocure (NVCR) announces that the U.S. FDA has approved the company’s Investigational Device Exemption ((IDE)) supplement, reducing the enrollment requirement for its LUNAR trial to 276 non-small cell lung cancer ((NSCLC)) patients with a 12 months follow-up.Shares up nearly ...

IDE supplement incorporates recommended changes from the interim analysis of the LUNAR trial conducted by an independent data monitoring committee Novocure (NASDAQ: NVCR) today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Investigat...

When you're hunting for stocks that could juice your portfolio with quadruple-digit percent increases, there's (at least) one big choice to make. Is it a better bet to go with an established business that's doing what nobody else can do in a way that's paying off more and more over time, or...

Medical device company Novocure 's (NASDAQ: NVCR) shareholders have been cheering the company's recent success in its phase 3 clinical trial as the stock responded on the good news from an independent data monitoring company's positive findings. On a Fool Live episode recorded...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q1 2021 Earnings Call Apr 29, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q1 2021 Earnings Call Transcript